The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Rational Development of Addiction Pharmacotherapies: Successes, Failures, and Prospects
Open accessAbstract
There are currently effective, U.S. Food and Drug Administration (FDA)-approved therapies for alcohol, nicotine, and opioid addiction. In some cases these therapeutics were rationally designed and tested using a combination of various animal models of addiction. In many cases, however, effective drug therapies for addiction were derived from the testing of compounds developed for other CNS disorders (e.g., analgesics and antidepressants), which were tested clinically in the absence of prior animal research using addiction models. This article will review the development of eight compounds that are currently most effective in the treatment of alcohol, opioid, and nicotine addiction with an emphasis on pharmacological mechanisms as well as the utility of animal models of addiction in the development of these therapeutics. In contrast to these successes, animal research has identified a number of promising medications for the treatment of psychostimulant addiction, none of which have proven to be effective clinically. This raises questions about the validity of current animal models of psychostimulant addiction. A specific example of an apparently promising pharmacotherapeutic for cocaine addiction (the D1 dopamine receptor antagonist ecopipam) that failed clinically will be examined to determine if this truly represents a challenge to the predictive validity of current models of cocaine addiction. In addition, the development of promising cocaine addiction therapeutics derived from animal research will be reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Dole, V. P. (1965) · JAMA · doi:10.1001/jama.1965.03090080008002 · Cited by 1,240
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270
Neuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201 · cited 1×
“More recent evidence revealed that acamprosate also is an mGluR5 receptor antagonist (De Witte et al. 2005).”
BackgroundAn open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study
Mardikian, P. N., LaRowe, S. D., Hedden, S., Kalivas, P. W., & Malcolm, R. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.001 · Cited by 179
Treatment of nicotine addiction: present therapeutic options and pipeline developments
Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135
Cited by
Refining deep brain stimulation to emulate optogenetic treatment of synaptic pathology
Creed, M., Pascoli, V. J., & Lüscher, C. (2015) · Science · doi:10.1126/science.1260776 · Cited by 280
Hamilton, L. K., Dufresne, M., Joppé, S. E., Petryszyn, S., Aumont, A., Calon, F., Barnabé-Heider, F., Furtos, A., Parent, M., Chaurand, P., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.001 · Cited by 284
Periodontal disease associates with higher brain amyloid load in normal elderly
Kamer, A. R., Pirraglia, E., Tsui, W., Rusinek, H., Vallabhajosula, S., Mosconi, L., Yi, L., McHugh, P., Craig, R. G., Svetcov, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.038 · Cited by 268
Howell, L. L., & Cunningham, K. A. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009514 · Cited by 262
CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank
Geurts, M. H., de Poel, E., Amatngalim, G. D., Oka, R., Meijers, F. M., Kruisselbrink, E., van Mourik, P., Berkers, G., de Winter-de Groot, K. M., Michel, S., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.01.019 · Cited by 222
Metadata
- Authors
- Christopher Pierce, R., O'Brien, C. P., Kenny, P. J., & Vanderschuren, L. J. M. J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-06-01
- Volume
- 2
- Issue
- 6
- Pages
- a012880-a012880
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2141487256
- Cited by
- 178
- References
- 8
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.